Domperidone Dosing in CKD
Domperidone does not require dose adjustment in chronic kidney disease regardless of eGFR, as it undergoes predominantly hepatic metabolism with minimal renal excretion of unchanged drug.
Pharmacokinetic Rationale
Domperidone's elimination profile makes it safe to use at standard doses across all stages of CKD:
- Hepatic metabolism is the primary clearance pathway, with the drug undergoing rapid and extensive metabolism via hydroxylation and N-dealkylation 1
- Minimal renal excretion of unchanged drug occurs, with only approximately 1% of urinary excretion representing unchanged domperidone 1
- Total urinary excretion accounts for only 31% of the oral dose, with most being metabolites rather than parent drug 1
- The drug is 91-93% protein bound, which remains stable in the absence of severe uremia 1
Dosing Recommendation
Use standard adult dosing without adjustment for renal function:
- The standard dose remains appropriate across all CKD stages (G1-G5) 1
- No dose reduction is needed even in end-stage renal disease 1
- Dialysis considerations are not necessary as the drug's pharmacokinetics are not significantly affected by renal replacement therapy 1
Clinical Context
This recommendation aligns with the general principle that drugs cleared predominantly by hepatic metabolism do not require renal dose adjustment 2. Unlike renally cleared medications that necessitate dose modifications based on eGFR 3, 4, domperidone's metabolic profile exempts it from such requirements.
Important Caveat
While renal dose adjustment is not needed, monitor for:
- Cardiac effects (QT prolongation risk exists independent of renal function)
- Drug interactions that may affect hepatic metabolism
- Hepatic impairment, which would be the primary concern for dose modification rather than renal function